Speedboat RS2 utilised at second NHS site

Speedboat RS2 advances beyond initial pilot centre

Chepstow, South Wales – 29 November 2017 – Creo Medical Group plc (AIM: CREO) is pleased to announce that Speedboat RS2 has been used by a second Gastroenterologist at a second NHS site to treat further patients. This follows the announcement earlier this year with the first patient being treated at St Marks hospital in London.

Initial feedback from the first two cases at this site confirmed the removal of lesions under local anaesthetic with a procedure time of under one hour. The patients were discharged on the same day and are now under routine follow-up and monitoring. We await final histology results.

Craig Gulliford, Chief Executive Officer of Creo Medical, commented:

We are excited by today’s announcement as it provides further validation of our technology. It is incredible that these patients were conscious, talking to the endoscopist and able to watch the procedure live on screen. While we need to collect additional supportive clinical data, we are encouraged by the results we’ve seen to date. We believe that procedures like this have the potential to eliminate the need for subsequent bowel surgery, with the obvious patient benefits aligned with material advantages to the healthcare system in terms of cost and patient safety.

Posted 11/29/17

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

19 March 2024

Welsh Labour Leader visits Creo’s facilities


05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi


31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific


10 January 2024

First Use of Speedboat® UltraSlim in Latin America


13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch


01 November 2023

Speedboat® UltraSlim: US FDA Clearance


25 October 2023

Speedboat UltraSlim: EU launch accelerated by 18 months


12 September 2023

Half Year Report: H1-2023


19 June 2023

Speedboat Inject cleared for upper GI use in Europe


01 June 2023

Speedboat™ Inject selected by NICE for assessment